Member Info for Jelenko

My personal target is 60p on or around 27th July!!

Well what exactly does mean anything in your world S.K. If they meant sod all they wouldn't bother keeping track.
Now I do add that I don't always believe the numbers all the time, especially since Trump took office, but that does not mean that they are not looked at within the oil industry.

It's important to remember that PMO get a premium to Brent prices. circa $3 I think

Correct Kenni.

Oh my God talk about doom and gloom merchants.

Saur,
If you are on your knees because of your own mistakes then yes but this is a hopefully short lived pandemic that nobody could have forecast. Even the banks are being told they can waive covenant measures during this period, governments around the world are lending companies money and we should not be held to ransom by a greedy opportunistic poxy hedge fund. The time to go shopping is now. I might add that Tony is at fault for dealing with these types in the first place as one who once worked at Lehman Bros. he SHOULD know better.

Saur,

You don't sell assets at the bottom of the market. You buy them. Buy low sell high, remember. No doubt you were against the E.O.N. deal that worked so well.

Oil has been strangely priced ever since Trump became president. The difference now is that He and every other oil producing nation wants it higher. Logic has nothing to do with anything in the markets any more. But rest assured, higher it will go. $40 Brent before May is out.

Don't forget PMO generally get a $3 premium to Brent.

Hi Ted,
I completely understand and it's not for me to advise anyone else on their investment strategy. It's unfortunate that Covid19 appeared on the scene because I feel sure that otherwise Agl would be over 80p now. However, we are where we are and in the case of Agl at the moment subject to Market Makers whims. From the various AGM's that I have attended it is clear that the major investors in Agl are looking for a substantial return on their investment A.N himself has banded a few numbers about in the past. This provides me with some comfort particularly in the absence of any real revenue income by which to measure valuation. Time of course is the big valuable unknown and buying this share now for a 12yr old's trust fund is a different proposition to me buying it now in my mid 60's!

Ted B
Classic. Buying shares when they go up but not when they go down and are cheaper. That is classic P.I. behaviour.
Don't get me wrong I am not being critical, but most of us feel more like buying in the blue and if it goes down feel like selling.
Exactly the opposite to what we should do e.g. Buy in the red, sell in the blue!! Good luck anyway.

No it's not. Under the De Novo application system the FDA have a maximum of 180 days to make a decision. The clock stops every time a question is asked but the Q submission and subsequent January meeting with the FDA was designed to eliminate/reduce questions and as such I hope it is less than the 180 days.

A bid at these levels... I know for a fact that the major shareholders are looking for a substantial return on their investment from the last placing so the answer to your comment is not in a month of Sundays would a bid be accepted this close to FDA .
And not at all at a price below £15. They can wait it out, it's PI's that are impatient.

On the face of it that sounds good but beware trying to use the extended settlement period to trade in and out of shares.
It's true that if you are on the right side of the market and catch it right you can make money from nothing, but beware because unless you can afford to pay for the shares in full it is easy to get burned buy a quick nosedive in the markets.
It happened to me in the 2008 crash even though I had done well previously It hurt in the end. Beware is my advice.

I think it's fair to say that there is not long to go before the company confirms that it has submitted it's FDA De Novo application document. share price should start to move up as MM's anticipate buying in the run up. Also, New ISA year starts in what, about 7 weeks. That in my book is a double Whammy. Most people wanting to invest in AGL will surely want it in an ISA and surely want to be in before FDA granted. Say no more!

All I can say is that A.N was pushed on this subject by someone at the AGM in October. His response after a pregnant pause was £5b mkt cap. Timescale 2-3yrs. He has also cited a number of players in the sector who have recently sold at £2b+ and they have a lot less to offer than Angle (according to A.N.) That translates in to a share price of around £30. Given where we are now that may sound crazy. But, there's always a but. He did say that to achieve that sort of number would require a Nazdaq listing . The UK investors don't have the money.

Woodford was not invested here. I checked that with the F.D. at the AGM. However, all small pharma type stocks suffered in the aftermath of Woodford's issues, AGL included. We haven't seen any really high volume days during the fall but logic dictates that as the FDA situation moves on the window to buy at relatively low prices diminishes. (Assuning a positive outcome)
Also, this is a big one tor ISA investing and I expect buying before April to use this years allowance and early buying in the new financial year ahead of potential FDA clearance shortly after. Time is our friend patience is rewarded more than impetuous frequent buying/selling. The future revenue stream and therefore profits for shareholders here is enormous and in my view wort waiting for. GLA

Parsortix can also test for RNA. BUT Parsortix Harvests live cells. Nobody else can do that. RNA certainly is not 99% accurate, so I'm not sure what Toshiba are trying to claim. Live cells are far more valuable. Japclap if you ask me.

They're not sells actually. Derivative providers can trade within the spread. There is always a matched trade someone buys and someone sells. What results are you on about Gawd ? No results due only FDA document to be submitted any time now and we know, because it was briefed that the targets were met.

Finncap know very well that even with one FDA approved application that this company will be worth substantially more than 135p, that valuation would be ludicrous given the opportunities that would then open for AGL. Finncap are no doubt filling the coffers of clients with cheap shares. If you want to see what valuation is possible look at Exact Sciences on Nazdaq and see how their sp. moved from $5 to $120 over a couple of years. AGL has more potential than them so I wouldn't ridicule anyone's view of high future valuations. £17 will be too cheap by 2021, in my view anyway.